Cohance Lifesciences Ltd

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 May 2026, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 11 July 2026, providing investors with the latest insights into its performance and valuation.

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 May 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 30 June 2026, providing investors with the latest view of the company’s position in the market.

At Rs 486.3, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Cohance Lifesciences Ltd locked at its upper circuit of 20% on 23 Jun 2026, with buyers queuing and no sellers willing to part with shares.

Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a remarkable spike in trading activity on 23 June 2026, with total traded value nearing ₹499.6 crores and volume exceeding 1.11 crore shares. The stock outperformed its sector by 11.7% and reversed a four-day losing streak, signalling renewed investor interest despite its strong sell rating and recent downgrade by MarketsMOJO.

The Sensex edged up 0.10% on 23 Jun 2026, but Cohance Lifesciences Ltd surged 8.81%, outperforming its Pharmaceuticals & Biotechnology sector by 6.14 percentage points. This sharp single-session gain rewrites the short-term narrative for the small-cap stock, raising the question of whether this is a genuine breakout or a relief rally within a broader downtrend.

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 19 June 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 May 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 08 June 2026, providing investors with the latest perspective on the company’s position.

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.

The Sensex edged up 0.51% on 19 May 2026, but Cohance Lifesciences Ltd outpaced the broader market with a robust 7.57% gain, marking a 4.75 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers. This sharp intraday advance rewrites the short-term narrative for the small-cap stock, raising questions about whether this is a genuine recovery or a technical bounce within a mixed trend.

Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reported a further deterioration in its financial performance for the quarter ended March 2026. Despite a marginal improvement in its financial trend score, the company continues to face significant headwinds, with sharp declines in profitability and sales growth contrasting starkly with broader market benchmarks.

Cohance Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Cohance Lifesciences Ltd has experienced a notable shift in its valuation parameters, moving from a very expensive to an expensive rating, reflecting changing market perceptions amid a challenging sector backdrop. Despite a recent downgrade in its Mojo Grade to Sell, the company’s valuation metrics and comparative analysis against peers reveal nuanced insights for investors navigating the Pharmaceuticals & Biotechnology space.